CTVA

Materials

Corteva

Price Chart

Market Data

Financials

XBRL · SEC EDGAR

2018–2025(8yr)

Revenue

Net Income

Free CF

Metric	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025Latest	YoY
Revenue	$14.3B	$13.8B	$14.2B	$15.7B	$17.5B	$17.2B	$16.9B	$17.4B	+2.9%
Gross Profit	$4.3B	$5.3B	$5.7B	$6.4B	$7.0B	$7.3B	$7.4B	$8.2B	+11.5%
Gross Margin	30.4%	38.1%	40.2%	41.1%	40.2%	42.4%	43.6%	47.3%	+3.6pp
Net Income	-$5.1B	-$959.0M	$681.0M	$1.8B	$1.1B	$735.0M	$907.0M	$1.1B	+20.6%
Net Margin	-35.5%	-6.9%	4.8%	11.2%	6.6%	4.3%	5.4%	6.3%	+0.9pp
Free Cash Flow	-$1.0B	-$93.0M	$1.6B	$2.2B	$267.0M	$1.2B	$1.5B	$2.8B	+81.8%
FCF Margin	-7.1%	-0.7%	11.2%	13.8%	1.5%	6.8%	9.2%	16.2%	+7.0pp
EPS (Diluted)	$-6.76	$-1.28	$0.91	$2.37	$1.58	$1.03	$1.30	$1.60	+23.1%

Total Debt$1.7B

Cash & Equiv.$4.5B

Net Cash$2.8B

3 min read

1. THE BIG PICTURE

Corteva is attempting to transition from a legacy chemical conglomerate into a high-margin, innovation-led agricultural specialist, but it remains tethered to its past. While it leads peers in gross margins and revenue growth, its bottom line is currently weighed down by massive GAAPGAAPGenerally Accepted Accounting Principles — the standard U.S. accounting rules all public companies must follow losses and environmental remediation costs that make its cash flow profile significantly weaker than its competitors.

2. WHERE THE RISKS HIT HARDEST

Corteva’s "Innovation Pipeline" and "Intellectual Property Estate" are threatened by "Third-Party Dependency" because Corteva relies on external licenses for key biotechnology traits (Risks). Any disruption in these contracts could stall the commercialization of the very products—such as ENLIST or PowerCore—that define its competitive edge. Furthermore, the "Direct Customer Access" provided by the Pioneer agency model is a strength that creates "Weather Sensitivity"; because Corteva deals directly with farmers, planting delays have a more immediate and outsized impact on its sales volumes than on competitors who sell through broader retail channels (Competitive Position).

3. WHAT THE NUMBERS SAY TOGETHER

Corteva presents a paradox: it boasts the highest gross margin in its peer group at 46.4%, yet it ranks 5th out of 6 in Free Cash Flow (FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders) margin at -8.6% (Peer Benchmarking). This disconnect suggests that while Corteva’s seeds and chemicals are premium-priced, the business is exceptionally expensive to run or is being drained by non-operating costs like the $537 million GAAPGAAPGenerally Accepted Accounting Principles — the standard U.S. accounting rules all public companies must follow loss reported in the most recent quarter (8-K). Revenue growth of 2.9% leads the peer group, but recent quarterly volumes fell 8% in the Seed segment and 2% in Crop Protection, indicating that growth is currently being sustained by price and product mix rather than expanding volume (8-K). Short interest is low at 1.6% of the float, suggesting that while cash flow is negative, the market is not yet betting on a structural collapse (Supplemental Signals).

4. IS IT WORTH IT AT THIS PRICE?

At a Forward P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations of 19.0x, Corteva is priced in line with the peer median of 19.7x. This valuation implies the market expects 3.2% long-term growth (CAPM analysis). This expectation appears grounded in reality given the TTMTTMTrailing Twelve Months — the most recent full year of financial data, updated on a rolling basis each quarter revenue growth of 2.9%, but it leaves little room for error if environmental liabilities exceed current accruals. While Corteva’s gross margins are exceptional at over 40%, its negative FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders margin of -8.6% makes it a laggard compared to peers like Ecolab (10.7%) or PPG (7.2%). If growth were to slow to a GDP-pace of 2.5%, the justified multiple would drop to 16.8x, representing roughly 12% downside from current levels (CAPM analysis).

5. WHAT WOULD CHANGE THIS VIEW?

Cautious if environmental remediation accruals increase significantly, as these liabilities are difficult to estimate and already impact cash flow (Risks).
Constructive if Seed and Crop Protection volumes return to growth in North America, reversing the 8% and 2% declines seen in the most recent quarter (8-K).
Cautious if the proposed corporate separation leads to higher borrowing costs or tax liabilities that erode the 2026 Operating EPSEPSEarnings Per Share — the company's net profit divided by its share count; the most common per-share profitability metric guidance of $3.45 to $3.70 (8-K, Risks).

6. BOTTOM LINE

Structural Advantage: A direct-to-farmer distribution model paired with a high-margin patent portfolio that captures premium pricing at the field level. Bottom Line: Corteva is a high-quality agricultural franchise currently obscured by legacy liabilities and negative cash flow, making it a fair-value play on farming innovation rather than a discounted opportunity.

Source: Synthesis · LLM Analysis

4 min read

1. Top 5 Material Risks

Environmental Remediation and Liabilities: Corteva incurs significant costs for pollution abatement and remediation related to its own operations and those of divested businesses (EIDP). Because remediation costs are difficult to estimate precisely, actual liabilities may be materially higher than current accruals.
Proposed Separation Risks: The plan to split into two standalone companies may not be completed on the announced timeline or at all. If completed, the resulting entities may face higher borrowing costs, operational dis-synergies, and potential tax liabilities if the IRS determines the spin-off is not tax-free.
Regulatory Approval Delays: The process for registering new biotechnology and crop protection products is lengthy and unpredictable. Funding or staff reductions at federal agencies like the EPA, USDA, and FDA can extend commercialization timelines, reducing the return on research and development investments.
Intellectual Property Challenges: Corteva’s business depends on protecting its patents and proprietary technology. Competitors are increasingly challenging these rights, and adverse outcomes could force Corteva to enter expensive license agreements or cease using key technologies.
Third-Party Dependency: Corteva relies on third-party licenses for biotechnology traits in its corn and soybean products. Failure by these partners to maintain or enforce their intellectual property, or disruptions in supply agreements, could prevent Corteva from selling its products.

2. Company-Specific Risks

Indemnification Obligations: Corteva is party to separation agreements with DuPont and Dow that involve uncapped indemnification for certain litigation and environmental liabilities. If these partners fail to satisfy their obligations, Corteva may be forced to bear these costs.
Counterfeit Products: Corteva’s global reputation makes its products targets for counterfeiters. The prevalence of these products can lead to lost sales and damage to consumer confidence in the integrity of Corteva’s brand.
Customer Credit Exposure: Corteva offers financing programs to farmers. In regions experiencing economic downturns or adverse growing conditions, customers may be unable to repay these debts, impacting Corteva’s cash flow and liquidity.
Pension Funding: Corteva maintains EIDP’s defined benefit pension plans. While no contribution is required for 2026, Corteva expects to evaluate discretionary contributions to the principal U.S. pension plan, which could be significant.

3. Regulatory/Legal Risks

Antitrust Scrutiny: Corteva is currently subject to pending lawsuits from the FTC and state attorneys general. These actions could result in fines, penalties, or restrictions on business practices.
Executive Order 12/6/2025: A presidential executive order directed the DOJ and FTC to investigate anti-competitive conduct in the food supply chain, including seeds. This could lead to increased regulatory costs and restrictions on future mergers and acquisitions.
Fraudulent Conveyance Claims: The separation from DuPont could be challenged under state and federal fraudulent conveyance laws. A court could potentially void the distribution or impose substantial liabilities on Corteva if it determines the separation left DuPont inadequately capitalized.
Tax Liability: Corteva is jointly and severally liable for the U.S. federal income tax of the DowDuPont consolidated tax reporting group for periods ending on or before the distribution. If DuPont or Dow cannot pay their allocated share, Corteva could be required to pay the entire amount.

4. Financial Impact Map

Environmental Remediation → Accrued Liabilities / Cash Flows → Remediation costs may be materially higher than current accruals due to geological complexity and the financial viability of other responsible parties.

Proposed Separation → Debt / Interest Expense → Potential for increased borrowing costs and dis-synergies that may exceed expectations.

Regulatory Approval Delays → Research and Development / Sales → Delays reduce the return on R&DR&DResearch & Development — spending on creating new products or technologies investments and impede the ability to meet sales and profitability metrics.

Indemnification Assets → Accounts and Notes Receivable / Other Assets → As of December 31, 2025, Corteva holds $242 million in accounts and notes receivable and $733 million in other assets related to indemnification agreements.

Customer Credit Risk → Accounts Receivable / Short-term Debt → Inability of customers to pay debts may require Corteva to issue more short-term debt to fund cash flow requirements.

Source: 10-K Item 1A · LLM Analysis

Recent Filings

Form	Filed	Period
10-K	Feb 2026	Dec 2025
8-K	Feb 2026	—
14A	Mar 2025	—